Navigation Links
Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus

se forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; and our short operating history; as well as those risks more fully discussed in the "Risk Factors" section of our most recent report on Form 10-K on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.

Contact

Alnylam Pharmaceuticals, Inc.
Investors:
Cynthia Clayton, 617-551-8207
or
Media:
KMorrisPR
Kathryn Morris, 845-635-9828


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:5/8/2008)... Nation,s Largest Renal Research Network Comple...34 Active Trials in Late Stage Development, EL SE...al Research(R),(DCR), a Phase I-IV clinical trial ...lated drug and device research and development for...nical trials in 2007 and has another 34,active tri...
(Date:5/8/2008)... Efficacy and safety data support potential of ase...phrenia and bipolar I disorder, WASHINGTON, May 8...tion,(NYSE: SGP ) today announced that an overvie...ogram was presented at the 161st Annual Meeting of...n, D.C., May 3-8. Data from,the studies, involving...
(Date:5/8/2008)... Results presented at the 27th Annual Meeting of ... (APS), SMYRNA, Ga., May 8 /-...tained pain relief from diabetic neuropathic pain ...ding to data presented at the,27th annual meeting ... "This is the first placebo-controlled trial of a...
(Date:5/8/2008)... HOUSTON, May 8 /- Go H...n of further clinical trials with Cholesterade (R)...t clinical group of 200,patients in 6 centers arou...dicine Institute at The Methodist Hospital in the ...trial. Dr. Bryan was formerly the Team,Physician f...
Breaking Medicine Technology:DaVita Clinical Research Completes Record Number of Renal Trials in 2007 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4Go Healthy Initiates Additional Clinical Tests on Cholesterade 2Major Community Health Organization Lowers TCO with Ericoms Alternative to Citrix 10362 1Major Community Health Organization Lowers TCO with Ericoms Alternative to Citrix 10362 2Major Community Health Organization Lowers TCO with Ericoms Alternative to Citrix 10362 3Michigan Dentists Giving Free Dental Care to Low Income Children During Annual Give Kids a Smile Program Starting February 1 10358 1Michigan Dentists Giving Free Dental Care to Low Income Children During Annual Give Kids a Smile Program Starting February 1 10358 2Michigan Dentists Giving Free Dental Care to Low Income Children During Annual Give Kids a Smile Program Starting February 1 10358 3AMERIGROUP Names Linda Whitley Taylor as Executive Vice President Associate Services 10356 1AMERIGROUP Names Linda Whitley Taylor as Executive Vice President Associate Services 10356 2AMERIGROUP Names Linda Whitley Taylor as Executive Vice President Associate Services 10356 3BioMed Central bolsters radiology image collection 10354 1
...WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - ...ity owned subsidiary of,Accentia Biopharmaceutical...blinded interim data from the start of its fast-tr...M) for Non-Hodgkin,s,lymphoma (NHL) from September... is the most recent data that has been made availa...
...Prophylaxis with Synagis Decreases Incidence of Re...nd GAITHERSBURG, Md., June 29, 2007,/PRNewswire-Fi...esults of a new study, published in the July issue...with Synagis(R) (palivizumab),may reduce recurrent...pecifically, the study showed that premature infan...
Other Medicine Technology:Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 2New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 3New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 4New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 5
(Date:5/11/2008)...e/ -- As the global community observes,the destruc...yclone of all,time and the associated mounting fru... victims, the Alumni Myanmar Institutes of Medicin...importantly, successful-in initiating,medical care...000 people,are assumed dead. AMIMA has funded the ...
(Date:5/11/2008)... -- The winners of today,s Susan G.,Komen Pittsbur...ace Overall Winners Male: Pat McGuire, Charl...bein, Pittsburgh, Pa., 19:19, 2nd Place Overall W...: Anna Beck, Washington, Pa., 19:22, 3rd Place O..., Pa., 16:13 Female: Jessica Winter, Pittsbu...
(Date:5/11/2008)...nd for Unveiling of the New Name of the ...HICAGO, May 11 /PRNewswire/ -- Thousands of people...ntry were present for the unveiling of the,new nam...t cancer,organization, This year, Y-ME National B...h anniversary. In celebration of this landmark, Y-...
(Date:5/10/2008)...orts to Gain Clearance for Airlift of ... May 10 /PRNewswire-USNewswire/ -- An AmeriCares,e...today to assess the,crisis situation and continue ...ion,s airlift of 15 tons of essential medicines an...king closely with the World Health Organization to...
Breaking Medicine News(10 mins):Health News:Alumni Myanmar Institutes of Medicine Association (AMIMA) Races Time to Help Cyclone Victims 2Health News:16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced 2Health News:Y-ME Makes Historic Announcement on Mother's Day 2Health News:Y-ME Makes Historic Announcement on Mother's Day 3Health News:AmeriCares Relief Worker Arrives in Myanmar 2
... government announced plans on Thursday to ban all... of the clitoris which just days ago cost the lif... which affects both Muslim and Christian women in ...he pharaohs, was banned in 1997 but doctors were a...
...alth Organization (WHO) has said that the risk of ...tely doubles after travel of four hours or more. ...the WHO, however, says that the absolute risk of d...d and immobile for more than four hours remains re...
...surgical students stick themselves with needles an... resulting injuries could be infectious and very ...a new study by reported Martin Makary, M.D., a sur...s Hospital, and colleagues, in the June 28 issue o...
...ls, a leading healthcare provider in Andhra Prades...llion during the next one year to set up new stat...are brand, which has just completed 10 years, plan... in Madhya Pradesh, Maharashtra, Chhattisgarh, Guj...
Other Medicine News:Health News:Egypt Outlaws All Female Circumcision 2Health News:Thrombosis Risk in Travel Lasting Over Four Hours is Higher: WHO 2Health News:Surgical Students Fail to Report Needle Stick Injuries 2Health News:Surgical Students Fail to Report Needle Stick Injuries 3
ACL 8000 is an easy-to-use, automated system that enables you to perform a wide array of assays for managing hemostatic disordersincluding D-Dimer, Von Willebrand Antigen and Free Protein S. Also off
...n Made Easy. The new generation FilterWire EZ Syst...ase of use, providing you with the confidence of g...asty procedures., ,The FilterWire EZ System ad... minimal changes to technique. The filter loop pr...
Representing the next step in the evolution of point-of-care testing, the i-STAT 1 Analyzer uses one platform to perform glucose strip testing along with all i-STAT test cartridges.
...ar over-the-wire left-heart lead is for use with c...-eluting lead has an angled shape and can be inser...method, giving physicians an extra option to succe...y of difficult venous anatomies. The Attain 4194 ...
Medicine Products: